Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
BUDZ
WEED, Inc.
Sangre AgroTech represents plant genomic research services, akin to contract research and development.
|
$4.08M |
$0.03
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
Sonnet's core pipeline is oncology-focused immunotherapies (e.g., SON-1010 IL-12) leveraging the FHAB platform.
|
$3.99M |
$1.28
+1.98%
|
|
BGLC
BioNexus Gene Lab Corp.
Chemrex pivot to biotech-focused CDMO activities positions it as a Contract Manufacturing Organization.
|
$3.95M |
$2.20
+1.02%
|
|
FBLG
FibroBiologics, Inc. Common Stock
Core business is fibroblast-based cell therapies (CYWC628, CYMS101, CybroCell) in regenerative medicine; directly matches Biotech - Cell Therapy.
|
$3.94M |
$1.55
+1.97%
|
|
SNOA
Sonoma Pharmaceuticals, Inc.
Eye care products, aligning with ophthalmic drug offerings.
|
$3.91M |
$2.30
+4.07%
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.77M |
$0.95
+2.56%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Calidi Biotherapeutics directly develops cancer therapies (oncolytic virus platforms) targeting oncology indications.
|
$3.77M |
$0.77
+4.55%
|
|
LADX
LadRx Corporation
LadRx is a biotechnology company focused on oncology drug development.
|
$3.70M |
$0.11
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is a recombinant lipase enzyme produced as a therapeutic for exocrine pancreatic insufficiency, fitting Recombinant Proteins & Enzymes.
|
$3.65M |
$2.96
+22.31%
|
|
BZYR
Burzynski Research Institute, Inc.
Company focuses on oncology therapeutics in biotech R&D.
|
$3.29M |
$0.02
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$3.28M |
$0.34
-3.64%
|
|
CASI
CASI Pharmaceuticals, Inc.
CID-103 is a monoclonal antibody therapeutic, a core product class for the company.
|
$3.22M |
$0.21
+2.99%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$3.20M |
$3.16
+9.72%
|
|
HIGR
Hi-Great Group Holding Company
KRAS gene license places HIGR in Biotech - Oncology, an oncology-focused biotech asset.
|
$3.18M |
$0.03
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$3.16M |
$0.05
+2.08%
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$2.81M |
$1.80
-8.38%
|
|
KALA
KALA BIO, Inc.
KPI-012 is a mesenchymal stem cell secretome (MSC-S) therapy, aligning with Biotech - Cell Therapy.
|
$2.67M |
$0.38
-5.27%
|
|
JAGX
Jaguar Health, Inc.
Jaguar Health focuses on crofelemer-based therapies delivered orally, aligning with the Oral Small Molecule Therapeutics category.
|
$2.54M |
$1.18
+3.98%
|
|
AIM
AIM ImmunoTech Inc.
Ampligen is AIM ImmunoTech's flagship oncology/immunotherapy platform and is being developed with cancer indications (pancreatic and ovarian cancer) in combination with checkpoint inhibitors.
|
$2.46M |
$0.91
|
|
BRTX
BioRestorative Therapies, Inc.
BRTX-100 is an autologous mesenchymal stem cell therapy, the company's lead cell therapy product for disc disease.
|
$2.34M |
$0.26
+1.98%
|
|
CARM
Carisma Therapeutics, Inc.
CAR-Macrophage platform is a cell-therapy technology, directly representing Carisma's core product category.
|
$2.33M |
$0.15
+196.92%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.15M |
$0.43
+4.90%
|
|
AAGH
America Great Health
Joint venture and activities in cell therapy and regenerative medicine.
|
$2.12M |
$0.00
|
|
BICX
BioCorRx Inc.
BioCorRx is actively commercializing Lucemyra, an FDA-approved oral small molecule therapeutic for opioid withdrawal, expanding direct product sales.
|
$2.02M |
$0.31
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
Company is a oncology-focused biotech developing radiation sensitizers and HDAC inhibitor therapeutics, with lead assets in Phase 2/preclinical stages.
|
$1.98M |
$1.79
-2.97%
|
|
YBGJ
Yubo International Biotech Limited
Endometrial stem cell research and potential cell therapies (core biotech focus).
|
$1.77M |
$0.01
|
|
REVB
Revelation Biosciences, Inc.
Core product focus on modulating innate immunity using the Gemini platform, aligning with Immunology Therapeutics.
|
$1.70M |
$1.15
-4.58%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$1.66M |
$1.12
|
|
CANF
Can-Fite BioPharma Ltd.
Company focuses on orally bioavailable small molecule therapeutics targeting A3AR, including Piclidenoson and Namodenoson.
|
$1.66M |
$3.20
-3.90%
|
|
ELAB
PMGC Holdings Inc.
Contract Research Organizations (CRO)-like R&D capabilities through PMGC Research Inc. for biotech development.
|
$1.63M |
$3.35
-13.12%
|
|
ERNA
Ernexa Therapeutics Inc.
Lead product is off-the-shelf allogeneic cell therapy using iPSC-derived mesenchymal stem cells (iMSCs).
|
$1.63M |
$0.19
-2.18%
|
|
PPCB
Propanc Biopharma, Inc.
Propanc Biopharma is a development-stage biotechnology company focusing on oncology therapies, making PRP its core candidate.
|
$1.49M |
$0.11
+3.01%
|
|
ENVB
Enveric Biosciences, Inc.
Enveric is focused on neuropsychiatric drug development with a lead program targeting neuroplasticity-based therapies.
|
$1.45M |
$5.21
-2.71%
|
|
SIGY
Sigyn Therapeutics, Inc.
Company’s cancer-related therapeutic platform focus places it in Biotech - Oncology.
|
$1.44M |
$0.08
|
|
ITRM
Iterum Therapeutics plc
ORLYNVAH is an oral small molecule antibiotic (sulopenem) that the company is launching commercially.
|
$1.34M |
$0.03
+4.00%
|
|
GRTX
Galera Therapeutics, Inc.
Company directly develops oncology therapeutics, including its NOS pan-inhibitor and SOD mimetics for cancer indications.
|
$1.31M |
$0.02
|
|
HCWB
HCW Biologics Inc.
HCWB's lead programs target oncology through novel immunotherapies, aligning with Biotech - Oncology.
|
$1.18M |
$0.65
+18.18%
|
|
CMND
Clearmind Medicine Inc.
CMND-100 is an oral small-molecule therapeutic candidate, categorizing the company under Oral Small Molecule Therapeutics.
|
$1.01M |
$0.68
-9.53%
|
Showing page 24 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
